Navigation Links
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Date:9/25/2007

phorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

Conventional, approved Xeloda dosing on a 14-on/7-off schedule is 1250 mg/m(2) twice daily (total of 2500 mg/m(2)/day).

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda.

For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindicated in patients with severe renal impairment. For patients with moderate renal impairment, dose reduction is required.

The most common adverse events (greater than or equal to 20%) of Xeloda monotherapy were diarrhea, nausea, stomatitis and hand-foot syndrome. As with any cancer therapy, there is a risk of side effects, and these are usually manageable and reversible with dose modification or interruption.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and qua
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
(Date:8/20/2014)... WEDNESDAY, Aug. 20, 2014 (HealthDay News) -- Leaving the car ... public transit is good for your health, a new study ... United Kingdom and found that 76 percent of men and ... men and 11 percent of women used public transit, and ... or walked. Those who drove to work weighed more ...
(Date:8/20/2014)... According to a new market ... SPD, Liquid Crystal, Microblinds, Thermographic and Photochromics), by ... others), by geography - Global Forecast to 2014 ... Smart glass market was worth $1581.4 Million in ... by 2020, at an estimated CAGR of 20% ...
(Date:8/20/2014)... Raleigh, NC (PRWEB) August 20, 2014 Doctors ... a way to wipe out mesothelioma in laboratory mice by ... Mesothelioma has just posted details of the study on its ... , Scientists with Hong Kong University’s AIDS Institute of ... death protein 1” or PD-1. By altering DNA, the vaccine ...
(Date:8/20/2014)... New Jersey’s Medical Marijuana Program has ... tens of thousands of patients in the state. However, ... that would expand the list of qualifying conditions and ... summer by State Assemblywoman Linda Stender, the need to ... growing. , To help fill the information gap for ...
(Date:8/20/2014)... OR (PRWEB) August 20, 2014 August ... are urged to become educated about eye health and ... examined. One frequently overlooked eye condition that must be ... Sharon Kleyne Hour Power of Water radio show, is ... children increasing exponentially, childhood dry eye is becoming a ...
Breaking Medicine News(10 mins):Health News:Want to Stay Slim? Leave the Car at Home 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 3Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 4Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 5Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3
... painkillers to treat inflammation are linked to an increased ... or flutter), concludes a study published on bmj.com ... drugs (NSAIDS) as well as new generation anti-inflammatory drugs, ... already been linked to an increased risk of heart ...
... Dennis Thompson HealthDay Reporter , SUNDAY, July 3 (HealthDay ... the summer air with dazzling colors and deafening sounds. But they ... year are harmed by fireworks, many of them maimed for life, ... care. "Where we see injuries is a lack of common ...
... N.C. July 4, 2011 Smoking cigarettes is a ... the smokers who choose to use one of the most ... the risk of serious cardiovascular events are on their way. ... Baptist Medical Center, in collaboration with researchers at Johns Hopkins ...
... Reinberg HealthDay Reporter , FRIDAY, July 1 (HealthDay ... are endorsing a U.S. health advisory panel,s recommendation that the ... breast cancer. The reason: There,s still a lack of ... Avastin was given fast-track approval by the U.S. ...
... The children most likely to walk or cycle to ... in an economically disadvantaged home, according to survey results that ... Pabayo of the University of Montreal Hospital Research Centre and ... is unique in that it follows the same group of ...
... the international aid community started to fund health programs ... support for tackling infectious diseases, and for implementing immunization ... and by governments are not always the same. New ... Globalization and Health uses ,agency theory, to examine ...
Cached Medicine News:Health News:Common painkillers linked to irregular heart rhythm 2Health News:Safety Experts Warn of Fireworks Dangers 2Health News:Safety Experts Warn of Fireworks Dangers 3Health News:Safety Experts Warn of Fireworks Dangers 4Health News:Chantix associated with 72 percent increased risk of serious CV events 2Health News: Avastin Rejection Supported by Cancer Experts 2Health News: Avastin Rejection Supported by Cancer Experts 3Health News: Avastin Rejection Supported by Cancer Experts 4Health News:Urban children are healthier commuters than rural teens 2Health News:Getting aid to where it is needed 2
... The Stryker Inter-Lock™ System ... surgery at the tibial fixation ... backup fixation into one implant. ... and can be used routinely ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
The Stryker Graft Workstation offers the surgeon flexibility in graft preparation. The posts are interchangeable and the system adapts to both soft tissue and bone grafts selection. Sizing gauges off...
... Medicine Knot Pusher is a reusable instrument used ... Knot Pusher is utilized in the handling and ... two piece shaft allows the surgeon to place ... pushing. The ring handle allows the surgeon ease ...
Medicine Products: